AAgilent Technologies

$160.00

$109.9952 weeks$160.00

Price

$160.00+42%1Y

1M+14%1Y+42%

Prices are end-of-day closes. This is a research view, the focus is on the fundamentals, quality and valuation below, not intraday price.

Smart Score

Above average

8/10

Value51

Quality86

Momentum61

Growth50

Strongest Quality, weakest Growth · ranked vs Healthcare peers. The five questions below judge the company on its own terms.

What they do

Our Life Sciences and Diagnostics Markets segment is comprised of seven areas of activity. We provide specialty contract development and manufacturing services for pharmaceutical customers as well as solutions that include reagents, instruments, software and consumables which enable customers in the clinical and life sciences research areas to interrogate samples at the cellular and molecular level.

In the company’s own words · 10-K filed Dec 22, 2025 · SEC EDGAR

P/E (TTM)32.2

Market Cap$35.89B

1Y Return+42%

5Y Return+8.0%

Business segments

Q2 2026 · $764.0M

The company’s own SEC segment disclosure.

Life Sciences And Diagnostics Markets$363.0M48%
Agilent Cross Lab$289.0M38%
Applied Markets$112.0M15%

Agilent Technologies (A) reported revenue of $1.83B in Q2 2026 (quarter ended April 30, 2026), up 10% from the same quarter a year earlier. That came with a gross margin of 54% and net income of $339M (18% of revenue). For the full year FY2025, revenue was $6.95B (+6.7% year on year) and net income $1.30B. Its largest segment in 2026-Q2 was Life Sciences And Diagnostics Markets at $363M, 48% of the disclosed total, just ahead of Agilent Cross Lab at 38%.

Raw charts

11 series · TTM

As reported to the SEC, without any scoring.

Diagnostics & Research

Ranks #16 of 29 by Smart Score